Consolidated Financial Results for the Three Months Ended June 30, 2025 PDF

Consolidated Financial Results

for the Three Months Ended June 30, 2025 [Japanese GAAP]

July 31, 2025

Company name: EIKEN CHEMICAL CO.,LTD. Listing: Tokyo Stock Exchange

Securities code: 4549

URL: https://www.eiken.co.jp/en/

Representative: Yuji Segawa President & CEO

Inquiries: Tomohiro Kudo Executive Officer Telephone: +81-3-5846-3379

Scheduled date to commence dividend payments: -

Preparation of supplementary material on financial results: Yes Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Three Months Ended June 30, 2025 (April 1, 2025 to June 30, 2025)

   1. Consolidated Operating Results (Percentages indicate year-on-year changes.)

      	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent
      Three months ended June 30, 2025 June 30, 2024	Millions of yen 10,197 9,519	% 7.1 (3.5)	Millions of yen 800 583	% 37.2 (44.6)	Millions of yen 813 641	% 26.8 (41.0)	Millions of yen 600 486	% 23.4 (36.8)

      (Note) Comprehensive income:	Three months ended June 30, 2025:	¥	605 million [	10.6%]
      	Three months ended June 30, 2024:	¥	547 million [	(31.4) %]

      	Basic earnings per share	Diluted earnings per share
      Three months ended	Yen	Yen
      June 30, 2025	18.21	18.04
      June 30, 2024	14.07	13.95

   2. Consolidated Financial Position

   	Total assets	Net assets	Capital adequacy ratio	Net assets per share
   As of June 30, 2025 March 31, 2025	Millions of yen 59,496 62,372	Millions of yen 41,754 43,598	% 69.6 69.3	Yen 1,266.29 1,294.08

   (Reference) Equity: As of June 30, 2025:	¥	41,396 million
   As of March 31, 2025:	¥	43,240 million

2. Dividends

   	Annual dividends
   	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
   Fiscal year ended March 31, 2025 Fiscal year ending March 31, 2026	Yen - -	Yen 26.00	Yen -	Yen 27.00	Yen 53.00
   Fiscal year ending March 31, 2026 (Forecast)		29.00	-	29.00	58.00

   (Note) Revision to the forecast for dividends announced most recently: None

   (Note) Breakdown of the 1st quarter dividend for the fiscal year ending March 31, 2026 : Commemorative dividend - yen

   Special dividend - yen

3. Consolidated Financial Results Forecast for the Fiscal Year Ending March 31, 2026(April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

1. Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

2. Changes in accounting policies, changes in accounting estimates, and restatement

   1. Changes in accounting policies due to revisions to accounting standards and other regulations: None

   2. Changes in accounting policies due to other reasons: None

   3. Changes in accounting estimates: None

   4. Restatement: None

3. Number of issued shares (common shares)

   1. Total number of issued shares at the end of the period (including treasury shares): June 30, 2025: 38,541,438 shares

      March 31, 2025: 38,541,438 shares

   2. Number of treasury shares at the end of the period:

      June 30, 2025: 5,850,078 shares

      March 31, 2025: 5,127,632 shares

   3. Average number of shares outstanding during the period:

Three months ended June 30, 2025: 32,985,383 shares

Three months ended June 30, 2024: 34,597,930 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

Table of Contents - Attachments

1. Overview of Consolidated Business Performance 2

   1. Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year 2

   2. Summary of Consolidated Financial Position for The First Quarter of The Current Fiscal Year 2

   3. Qualitative Information Regarding Forecasts for Consolidated Business Performance 3

2. Quarterly Consolidated Financial Statements and Primary Notes 4

   1. Quarterly Consolidated Balance Sheet 4

   2. Quarterly Consolidated Statements of Income and Comprehensive Income 6

      Quarterly Consolidated Statements of Income

      For the three months 6

      Quarterly Consolidated Statements of Comprehensive Income

      For the three months 7

   3. Notes to Quarterly Consolidated Financial Statements 8

(Notes on going concern assumption) 8

(Accounting methods adopted particularly for the preparation of quarterly consolidated

financial statements) 8

(Notes in case of significant changes in shareholders' equity) 8

(Notes on Cash Flow Statement) 8

(Segment information) 8

(Significant subsequent events) 8

1. Overview of Consolidated Business Performance

   1. Summary of Consolidated Business Performance for The First Quarter of The Current Fiscal Year

      During the first quarter of the current fiscal year, the domestic and overseas economies remained unstable due to surging resource prices, geopolitical risks, U.S. trade policies, and monetary policies of major countries.

      The business environment became increasingly severe in the clinical diagnostics industry due to continued measures to cap medical expenses and rising costs such as for logistics and raw material procurement, etc., on account of yen depreciation and high crude oil prices. Corporations are being forced to focus on greater cost competitiveness and to actively expand into overseas markets.

      In the context of this business environment, the Eiken Group is implementing key measures focused on the three key business fields of "Contribution to cancer prevention and treatment," "Contribution to the eradication and control of infectious diseases," and "Provision of products and services useful for health care," under the slogan "Challenges to Innovation" in accordance with the Medium-term Management Plan established based on the Group's management framework "Eiken Road Map 2030." The Group is striving to fundamentally transform its business to strengthen its earnings base.

      In addition, as a Group with a mission to protect the health of people worldwide, the Eiken Group is addressing issues not only in "Medical" but also in the "Environment," "Society," and "Governance." Through this, we strive to further enhance our corporate value and achieve a sustainable society.

      The net sales for the consolidated fiscal year under review increased to 10,197 million yen (up 7.1% year-on-year) due to strong growth in overseas sales. For net sales by product class and type, sales of microbiological testing reagents were 1,081 million yen (up 2.2% year-on-year), and sales of urinalysis reagents were 1,187 million yen (up 5.9% year-on-year) due to growth in sales of test strips for overseas markets. Sales of immunological and serological reagents were 5,956 million yen (up 6.3% year-on-year) due to strong sales of fecal immunochemical test reagents for overseas markets and products introduced and sold from Tosoh Corporation. Sales of clinical chemistry reagents were 149 million yen (down 0.8% year-on-year), and sales of the equipment and culture medium for food and environment related category were 473 million yen (down 7.5% year-on-year). Sales in other category (medical devices, genetic-related products, etc.) were 1,347 million yen (up 25.6% year-on-year) due to increased sales of medical devices for overseas markets and genetic-related products for domestic markets. Overseas sales were 2,763 million yen (up 30.7% year-on-year) due to strong growth in sales of fecal immunochemical test reagents, urinalysis reagents, and medical devices.

      Regarding profit, due to the increase in overseas sales, operating profit was 800 million yen (up 37.2% year-on-year), ordinary profit was 813 million yen (up 26.8% year-on-year), and profit attributable to owners of parent was 600 million yen (up 23.4% year-on-year).

   2. Summary of Consolidated Financial Position for The First Quarter of The Current Fiscal Year

      The financial position at the end of the first quarter of the consolidated accounting period under review was as follows.

      When compared to the end of the previous consolidated fiscal year, total assets decreased by 2,875 million yen, liabilities decreased by 1,032 million yen, and net assets decreased by 1,843 million yen.

      Major increases and decreases in the category of assets were a decrease of 5,204 million yen in cash and deposits. In addition, property, plant and equipment increased by 1,133 million yen due to the construction of the new manufacturing building at Nogi Division. In the category of liabilities, notes and accounts payable - trade decreased by 392 million yen. In the category of net assets, despite the recording of profit attributable to owners of parent, shareholders' equity decreased by 1,847 million yen due to the payment of dividends and acquisition of treasury shares.

      As a result, the equity ratio increased from 69.3% at the end of the previous fiscal year to 69.6%.

   3. Qualitative Information Regarding Forecasts for Consolidated Business Performance

   For the consolidated financial results forecasts for the six months ending September 30, 2025 and the consolidated fiscal year ending March 31, 2026, there has been no change in the financial forecast announced on May 13, 2025.

2. Quarterly Consolidated Financial Statements and Primary Notes

(1) Quarterly Consolidated Balance Sheet

(Millions of yen)

As of March 31, 2025 As of June 30, 2025

Assets

Current assets

Notes and accounts receivable - trade, and contract

assets

10,928 11,177

(Millions of yen)

As of March 31, 2025 As of June 30, 2025

Liabilities

Current liabilities

23

Quarterly Consolidated Statement of Comprehensive Income (For the three months)

(Millions of yen)

For the three months ended June 30, 2024

For the three months ended June 30, 2025

Comprehensive income attributable to non-controlling

interests - -

(3) Notes to Quarterly Consolidated Financial Statements (Notes on going concern assumption)

Not applicable.

(Accounting methods adopted particularly for the preparation of quarterly consolidated financial statements) (Tax expense calculation)

Tax expenses on profit before income taxes are calculated by multiplying profit before income taxes by the reasonably estimated effective tax rate for the consolidated fiscal year including the first quarter of the consolidated accounting period under review after applying tax effect accounting.

(Notes in case of significant changes in shareholders' equity)

(Acquisition of treasury shares)

In accordance with resolution of a meeting of the Board of Directors held on October 31, 2024, the Company acquired 722,400 treasury shares. As a result, for the first quarter of the current fiscal year, treasury shares increased by 1,546 million yen.

(Notes on Cash Flow Statement)

Quarterly consolidated statements of cash flows for the first quarter of the current fiscal year are not prepared.

Depreciation (Including depreciation of intangible assets.) for the first quarter of the current fiscal year is as follows.

Previous consolidated fiscal year (From April 1, 2024

to June 30, 2024)

(Millions of yen)

Current consolidated fiscal year (From April 1, 2025

to June 30, 2025)

Depreciation 546 548

(Segment information)

1. Previous consolidated fiscal year (From April 1, 2024 to June 30, 2024)

   The Group is a single segment of the reagents business, so it is omitted.

2. Current consolidated fiscal year (From April 1, 2025 to June 30, 2025)

The Group is a single segment of the reagents business, so it is omitted.

(Significant subsequent events)

In accordance with resolution of a meeting of the Board of Directors held on May 13, 2025, the Company resolved to transfer all equity interests in its specified subsidiary, EIKEN CHINA CO., LTD., and entered into an equity transfer agreement on July 31, 2025.

For details, please refer to the "(Update on Disclosed Matter) Notice Concerning Transfer of Equity Interests of Consolidated Subsidiary and Recording of Extraordinary Income" announced on July 31, 2025.